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Access Campaign
MSF
« Monitoring treatment efficacy in the context of resource limited settings », 
TULP01, WAC , Toronto 2006Viral Load use 
between 2001-2005
z MSF programs:
z VL was not routinely available nor recommended
z The lack of laboratory monitoring should not delay
treatment initiation in any case.
z WHO 2003 guidelines
z VL is not being recommended to inform ‘When to Start’
decision making. 
z VL is not to be used as sole criterion for treatment 
failure at this time but availability encouraged.
z If available, suspected clinical and/or CD4 failure 
should trigger ordering this test.
WHO guidelines 2003 – a public health approachz When to start: 
z “HIV-RNA (viral load) measurement is not 
necessary prior to initiating ART “
z Wide agreement regarding the impact of CD4 T cell 
count on survival after initiation of HAART
z Initiation of a life long treatment (exposing the patient 
to side effect) based on VL when CD4 are well above 
a threshold of 350 is subject to controversy.
z VL is of negligible pronostic value among adherent 
patients with more than 200 CD4* .
2006 WHO recommendations (1) 
*Wood E and al, AIDS 2006, 20:1197-11982006 WHO recommendations (2)
z Defining treatment failure: 
z “The field needs to move toward (…)implementation of 
affordable VL testing. CD4 and plasma HIV-1 RNA 
testing are not luxuries. They are (…) invaluable 
measures of program monitoring”.
z The threshold:
Table 8 - Clinical, CD4 Cell Count, and Virological Definitions of Treatment Failure
for Patients on a First-Line Antiretroviral Regimen for at Least Six Months
Clinical failure Occurrence of new or recurrent WHO stage 4 condition
CD4 cell failure • Fall of CD4 count to pre-therapy baseline (or below) or
• 50% fall from the on-treatment peak value (if known) or
• Persistent CD4 levels < 100 cells/mm3
Virological failure Plasma HIV-1 RNA level >10,000 copies/ml a
a. The optimal viral load value at which ART should be switched has not been defined. However, values of more than 10,000 
copies/ml have been associated with subsequent clinical progression and appreciable CD4 cell count decline.What did happen?
WHY use VL?1. Program matureMSF presented data on 57’147 patients
- Few patients on second line:
z MSF data show that patients starting ARV at a very advanced
stage have excellent outcome (May 2006). 
z Median CD4 104, 84% WHO stage 3 and 4) –
z 9% death, 10% LTFU (<3m)
z Probability of survival of 84% (74%) at 2 years (death only versus 
death + lost to follow-up) 
z Median follow-up is 9 months
z 1-3% of patients are on a second line regimen
z 3% of patients at 48 months
z The median duration of a first line regimen in the
US is 1.6 years*. 
* Chen RY Clin Inf Dis 2003; 37:714-722Why do we rarely switch?
z The availability of a second line
z Switching too early may leave patients without
treatment options
z T h ec r i t e r i au s e dt o  d e f i n efailure
z CD4 have a poor predictive value for failure*
 OI might jeopardize CD4 rise
 51% patients identified with CD4 failure had
VL< 50**
z No experience on when to switch if not using the
fully suppressive strategy (DART and CDC studies still
ongoing but main outcome is clinical)
•CROI 2006 
•**Pepfar meeting 2006, SA, Cardellio and al0.6%
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The experience of Khayelitsa, SA
Months:
ART programmes mature and growing number of
patients will inevitabely fail. Detection of treatment
failure will be the next burning issue.2. Strategy to preserve
the first lineWhy and How to Wait?
z First line is cheap, easy to take, easy to store.
z Switching early enough in order to protect the 
patient from the occurrence of severe 
immunosuppression.
z Prevent the accumulation of resistance that would 
preclude future treatment options.The fear for resistance: 
accumulation of mutation over time
z The main rational of using VL as a monitoring for 
early virological escape is resistance issue
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With the courtesy of S YerlyThe when to switch strategy 
needs revisiting: DHHS guidelines
“There is no consensus on the optimal time to 
change therapy for virologic failure. 
The most aggressive approach would be to 
change for any repeated, detectable viremia . . .”
However
“ . . . a decision to change regimens might reduce future 
treatment options for that patient . . .”
Patients in LDC are in the same situation as experienced
patients in wealthy coutrnies.
How did we arrive to a threshold of 10’000?The 10’000 Threshold: 
PLATO study
-100
-50
0
50
100
<300 300-
10,000
10,000-
30,000
>30,000
Untreated, WT
(N=205)
Treated, MDR
(N=628)
PLATO study, Lancet 2004What did PLATO suggest?
z Goal: Maintening CD4 above a threshold of
200 cells per µl.
« Treatment regimen that maintains the viral 
load below 10’000 copies (…) do not seem to 
be associated with appreciable CD4-cell 
count decline »
z Other cohort studies to confirm this trend*
* ICONA cohort, 3. Tools availableSimplification is NOT
antagonist to the use of VL
z Cheaper, new technologies have become available for 
both CD4 and VL
z The goal: lab comes to the patients, instead of the
patient going to the lab:the point of care test…
z DBS allows a simple transportation 
z Semi-quantitative test might be as useful as quantitative results
(survey in MSF sites, WAC Toronto,  abstract number 14/08 
MOPE0155 Dineva M; Goncalves G Guillerm M)
z Point of care VL test are highly desirableThe simplification paradox
How can we advocate for simplified, standardised guidelines, 
and continuously keep asking for tests, new research?
Cheaper, new technologies have become available for both CD4 and VL
The goal: lab comes to the patients, instead of the patient going to the
lab: the point of care test…
DBS allows a simple transportation 
Semi-quantitative test might be as useful as quantitative results (survey in 
MSF sites, WAC Toronto,  abstract number 14/08 MOPE0155 Dineva M; 
Goncalves G Guillerm M)<400 
copies/ml
400-10000 
copies/ml
>10000 
copies/ml
The disptick: 
a qualitative measurement of VLPerspective for the
use of VL 
All those points led WHO to introduce
VL as a key player in the when to 
switch question –
However immense benefit could be
obtained for long term management:How can we maximize  survival and 
quality of life  for 10 years with two 
lines of ARV treatment?1) Early Adherence monitoring: 
response to an early elevated VL
3 month 6 month
>= 12 
months Total
n 114 54 64 232
< 400 75% 61% 48% 64%
>=400 10% 9% 25% 14%
Subsequent result after a first result >=400 copies/ml
Khayeslitsa, 
D Coetzee, 
E Goemare
K HildebrandImportance of strengthening 
early adherence
z The chances of returning to below 400 copies/ml 
after rebound are inversely proportional to 
duration of viremia. 
z Adherence checks using viral load 4 months 
post-HAART initiation allows health care workers 
to institute adherence interventions early. 
This strategy was helpful to keep poorly 
adherent patients on their first-line regimen.2) Switching a regimen
z The context:
z Clinic and CD4 limitations
z Algorithm to predict virological failure with clinic and
patients history have been developped* but not validated**
z The goal:
z Intervention before the patient get severely
immunosuppressed
z The drugs:
z Strong independant second line including boosted PI
*Colebunders and al, LID 2006
**Lawn and al, LID 2006BREAKING THE 
VIROLOGICAL 
DOGMA 
moving out of the intensive 
suppressive strategy3) The sentinel monitoring
z Viral load testing also serves as a tool to assess HIV programme
quality
z The WHO has proposed that 70% of patients should achieve 
virological suppression (<400 copies/ml) at six months on ART in
resource-limited settings as a quality benchmark 
z The availability of simple, affordable viral load tests would 
expand the number of sites undergoing quality assessments, as 
well as the scope of studies investigating predictors of treatment 
failure
z Further research using simple viral load tests is needed to 
monitor programme effectiveness, assess adherence 
interventions, and identify factors associated with virological
failure across a diversity of settings (such as urban versus rural 
care, and clinic versus home-based care). VL is not a luxury VL is not a luxury
z There is a place for a wise use of a semi-quantitative VL in 
developing countries
- Help keeping the 1st line longer in detecting early 
escape 
- Help preventing the prescription of useless 2nd line 
- Help to prevent the occurrence of severe 
immunodeficiency 
- Help monitor large scale programs
- Cost-effectiveness studies have not been performed 
yetViral load is not a luxury in LRS Viral load is not a luxury in LRS
z z There is a place for a wise use of a semi There is a place for a wise use of a semi- -
quantitative VL in developing countries quantitative VL in developing countries
z z Help keeping the 1 Help keeping the 1st st line longer  line longer 
by detecting early escape  by detecting early escape 
z z Help preventing the prescription of useless 2 Help preventing the prescription of useless 2nd nd line  line 
z z Help to prevent the occurrence of severe  Help to prevent the occurrence of severe 
immunodeficiency  immunodeficiency 
z z Critical to monitor large scale programs Critical to monitor large scale programs
z z Cost Cost- -effectiveness studies have not been  effectiveness studies have not been 
performed yet performed yet
z z The point of care test would be the most suitable  The point of care test would be the most suitable 
test for use  test for use - -end…Reluctance to switch when 
future options are rare
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2 consecutive viral loads above
5000 copies/ml
Starting 2nd-line 
regimen
Cumulatively 11.9% (95% CI 7.6 – 18.4) of 
patients were on second-line by 3 years 
on ART.  Khayelitsa, South Africa, with the
courtesy of D Coetzee and E Goemaerez No switch occur the first year of treatment
z High threshold for switch (10’000 copies)
z Routine VL and CD4
z once a year (CD4 recommanded q6 months)
OR
z Trigger is a clinical event
z Trigger is discordance (CD4 decrease in the 
absence of clinical symptoms)